Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. develops clinical-stage biopharmaceutical programs for brain diseases and other underserved, prevalent diseases. News for NMRA centers on neuroscience drug development, financial results, business updates, and presentations at healthcare conferences.
Recurring updates describe pipeline programs such as navacaprant for major depressive disorder, NMRA-511 for Alzheimer’s disease agitation, M4 muscarinic receptor positive allosteric modulators including NMRA-861 and NMRA-898, and NMRA-215, an oral brain-penetrant NLRP3 inhibitor. Company announcements also cover clinical study results, development strategy, cash runway commentary, and program prioritization across neuropsychiatric and neurodegenerative disease areas.
Summary not available.
Summary not available.
Summary not available.
Summary not available.